A 2-Stage, Single-Dose Study in Healthy Volunteers and COPD Patients With an Open Label Ipratropium Bromide Reference to Evaluate the Efficacy, Pharmacokinetics, and Safety Profile of Inhaled TV46017
Phase of Trial: Phase I
Latest Information Update: 04 Sep 2015
At a glance
- Drugs TV 46017 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Teva Pharmaceutical Industries
- 28 Aug 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 25 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.